<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028374</url>
  </required_header>
  <id_info>
    <org_study_id>2021-036</org_study_id>
    <nct_id>NCT05028374</nct_id>
  </id_info>
  <brief_title>COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies</brief_title>
  <official_title>Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether protective antibody levels increase after booster dosing with the&#xD;
      Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low&#xD;
      antibody levels after a prior first vaccination with any of the SARS-CoV2 vaccines that were&#xD;
      authorized for use in the USA. Researchers will also assess whether the booster dosing with&#xD;
      the Moderna COVID-19 vaccine is safe in patients with multiple myeloma, amyloidosis, or other&#xD;
      blood cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific hypothesis being tested is that it may be possible to induce a protective&#xD;
      humoral immune response with a booster dose of the Moderna COVID-19 vaccine in patients with&#xD;
      hematologic malignancies who did not have an adequate response to first vaccination with any&#xD;
      of the available COVID-19 vaccines. To test this hypothesis, t a Phase II singlestage trial&#xD;
      in which patients with a negative or weak positive anti-SARS-CoV2 IgG antibody test (defined&#xD;
      as &lt;1.00 S/CO and 1.00-1.99 S/CO, respectively) will receive a single standard dose of the&#xD;
      Moderna COVID-19 vaccine intramuscularly, and then have anti-SARS-CoV2 IgG antibody levels&#xD;
      checked 28 days (+/-3 days) later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed response rate of anti-SARS-CoV2 antibody seroconversion.</measure>
    <time_frame>28 days (+/- 3 days) following a booster dose of the Moderna mRNA COVID-19 vaccine</time_frame>
    <description>Anti-SARS-CoV2 IgG antibody seroconversion from negative to positive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed AEs and SAEs</measure>
    <time_frame>Daily phone calls or video chats for 1 week following vaccine administration, and then weekly after that until 4 weeks after vaccination.</time_frame>
    <description>Safety Assessments for AEs and SAEs will be graded according to CTCAE v4 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed rate of STRONG POSITIVE anti-SARS-CoV2 antibody response</measure>
    <time_frame>measured 28 days (+/- 3 days) following a booster dose of the Moderna COVID-19 vaccine.</time_frame>
    <description>A STRONG POSITIVE response is defined in this trial as an anti-SARS-CoV2 IgG antibody titer of at least 2 S/CO 28 days (+/- 3 days) following vaccine administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">171</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>AL Amyloidosis</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>A single &quot;booster&quot; dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The dose of Moderna mRNA vaccine to be administered is the same for all patients in all enrollment cohorts: 0.5 mL administered intramuscularly as a single dose, according to the manufacturer's package insert.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A single &quot;booster&quot; dose of the Moderna mRNA COVID-19 vaccine</intervention_name>
    <description>All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.</description>
    <arm_group_label>A single &quot;booster&quot; dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly</arm_group_label>
    <other_name>Covid 19 booster dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 18 years of age or older&#xD;
&#xD;
          4. Previously diagnosed with MM/AL amyloidosis (Cohorts 1 or 3) or other hematologic&#xD;
             malignancy (Cohorts 2 or 3).&#xD;
&#xD;
          5. Previously received any one of the available COVID-19 vaccines (between 4 and 36 weeks&#xD;
             prior to enrollment)&#xD;
&#xD;
          6. Anti-SARS-CoV2 IgG antibody titer of results less than 1.0 units (Cohorts 1 and 2), or&#xD;
             1.0-1.99 units (Cohort 3). Antibody titers will be measured within 14 days of&#xD;
             enrollment.&#xD;
&#xD;
          7. If currently receiving potentially immunosuppressive anti-neoplastic therapy for their&#xD;
             underlying hematologic condition, a two-week interruption in therapy before and after&#xD;
             the booster dose of vaccine is ENCOURAGED BUT NOT REQUIRED (physician discretion).-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Daily corticosteroids at a dose equivalent to Prednisone 20 mg/day or greater during&#xD;
             the period two weeks before enrollment to the trial. Intermittent steroid dosing at or&#xD;
             above this level is permitted (i.e., weekly dexamethasone dosing as part of myeloma&#xD;
             therapy)&#xD;
&#xD;
          2. History of previous severe reaction to any available COVID-19 vaccine (defined as any&#xD;
             Grade 3 or higher reaction)&#xD;
&#xD;
          3. Febrile illness within 3 days of booster dosing.&#xD;
&#xD;
          4. Documented SARS-CoV2 infection within 2 weeks of enrollment.&#xD;
&#xD;
          5. Less than 3 months post-autologous or allogeneic stem cell transplant (NOTE:&#xD;
             transplant between initial standard vaccine administration and enrollment is NOT&#xD;
             otherwise grounds for exclusion from participation).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A. Zonder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy Galasso, RN</last_name>
    <phone>313-576-8453</phone>
    <email>galassoc@karmanos.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffrey Zonder, MD</last_name>
    <phone>313-576-8673</phone>
    <email>zonderj@karmanos.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey A. Zonder</last_name>
      <phone>313-576-9363</phone>
      <email>zonderj@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey A. Zonder, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abhinav Deol, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jay Yang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Runge-Moris, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asif Alavi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Kin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asfar Azmi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Uberti, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lois Ayash, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dipenkumar Modi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey Zonder</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

